Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Malin ( (MLLNF) ) has issued an announcement.
Malin Corporation plc reported its 2025 interim results, highlighting a significant milestone with the sale of Poseida, which contributed to a capital return of €150 million to shareholders. Despite a decrease in intrinsic equity value due to the divestment and a downward revision in Viamet’s valuation, Malin maintains a strategic focus on maximizing shareholder value through its investments in life sciences. The company’s cash position decreased slightly due to normal operations, and it continues to monitor potential contingent payments from previous sales, such as Kymab and Poseida.
More about Malin
Malin Corporation plc is a company focused on investing in highly innovative life sciences companies. It aims to create shareholder value through long-term capital and strategic expertise in global healthcare businesses. Malin is headquartered in Ireland and listed on the Euronext Growth Dublin.
Find detailed analytics on MLLNF stock on TipRanks’ Stock Analysis page.